Abstract
Objective
Patients and Methods
Results
Conclusion
Abbreviations and Acronyms:
ADC (apparent diffusion coefficient), DTI (diffusion tensor imaging), FLAIR (fluid-attenuated inversion recovery), MCSA (Mayo Clinic Study of Aging), MRI (magnetic resonance imaging)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Mayo Clinic ProceedingsReferences
- Incidental findings on brain magnetic resonance imaging: systematic review and meta-analysis.BMJ. 2009; 339: b3016
- Prevalence of abnormal findings on brain magnetic resonance (MR) examinations in adult participants of brain docking.BMC Neurol. 2005; 5: 18
- Incidence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study.Stroke. 2003; 34: 392-396
- Silent brain infarcts: a systematic review.Lancet Neurol. 2007; 6: 611-619
- Incidental findings on brain MRI in the general population.N Engl J Med. 2007; 357: 1821-1828
- Incidental acute infarcts identified on diffusion-weighted images: a university hospital-based study.AJNR Am J Neuroradiol. 2008; 29: 937-940
- Incidental magnetic resonance diffusion-weighted imaging-positive lesions are rare in neurologically asymptomatic community-dwelling adults.Stroke. 2014; 45: 2115-2117
- Prevalence and risk factors of acute incidental infarcts.Stroke. 2015; 46: 2722-2727
- Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy.Neurology. 2009; 72: 1230-1235
- Predictors of highly prevalent brain ischemia in intracerebral hemorrhage.Ann Neurol. 2012; 71: 199-205
- The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics.Neuroepidemiology. 2008; 30: 58-69
- History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population.Mayo Clin Proc. 2012; 87: 1202-1213
- Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative.Alzheimers Dement. 2010; 6: 212-220
- Vascular diseases of the brain.in: Neuroradiology: The Requisites. 4th ed. Elsevier, Philadelphia, PA2017: 87-149
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.Lancet Neurol. 2013; 12: 822-838
- Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical-trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.Stroke. 1993; 24: 35-41
- Silent ischemic infarcts are associated with hemorrhage burden in cerebral amyloid angiopathy.Neurology. 2010; 74 (author reply 93): 93
- Cerebral microinfarcts: the invisible lesions.Lancet Neurol. 2012; 11: 272-282
- Are acute infarcts the cause of leukoaraiosis? Brain mapping for 16 consecutive weeks.Ann Neurol. 2014; 76: 899-904
- Detection, risk factors, and functional consequences of cerebral microinfarcts.Lancet Neurol. 2017; 16: 730-740
- Silent brain infarcts and the risk of dementia and cognitive decline.N Engl J Med. 2003; 348: 1215-1222
- Population-based prevalence of cerebral cavernous malformations in older adults: Mayo Clinic Study of Aging.JAMA Neurol. 2017; 74: 801-805
- Covert neurological symptoms associated with silent infarcts from midlife to older age: the Atherosclerosis Risk in Communities study.Stroke. 2012; 43: 1218-1223
Article Info
Publication History
Footnotes
Grant Support: This work was supported by grants K76 AG057015-01 (principal investigator [PI]: J.G.-R.), R01 NS097495 (PI: P.V.), U01 AG06786 (PI: R.C.P.), P50 AG16574 (PI: R.C.P.), R01 AG034676 (PI: Rocca), R01 AG11378 (PI: C.R.J.), and R01 AG041851 (PIs: C.R.J. and D.S.K.) from the National Institutes of Health (NIH); the Gerald and Henrietta Rauenhorst Foundation grant; the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; and the Elsie and Marvin Dekelboum Family Foundation. The funding sources were not involved in the manuscript review or approval.
Potential Competing Interests: Dr Mielke consults for Eli Lilly and Lysosomal Therapeutics, Inc. She receives research grants from the National Institutes of Health (NIH)/National Institute on Aging, Department of Defense, Biogen, Roche, and Lundbeck. Dr Vemuri received grants R01 NS097495 and P50 AG016574/P1 from the NIH. Dr Kantarci serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc, and on the data monitoring boards of Pfizer and Janssen Alzheimer Immunotherapy; and is funded by grants from the NIH (grant nos. R01 AG040042 [PI], R21 NS066147 [PI], P50 AG44170/Project 2 [PI], P50 AG16574/Project 1 [PI], and R01 AG11378 [Co-I]). Dr Brown receives research support from the NIH. Dr Knopman serves on a data safety monitoring board for Lundbeck Pharmaceuticals and for the Dominantly Inherited Alzheimer Network (DIAN) study; is an investigator in clinical trials sponsored by Biogen, TauRX Pharmaceuticals, Lilly Pharmaceuticals, and the Alzheimer's Disease Cooperative Study; and receives research support from the NIH. Dr Jack serves on the scientific advisory board for Eli Lilly & Company; receives research support from the NIH/National Institute on Aging, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Foundation; and holds stock in Johnson & Johnson. Dr Petersen serves on data monitoring committees for Pfizer, Inc, and Janssen Alzheimer Immunotherapy; is a consultant for Biogen, Roche, Inc, Merck, Inc, and Genentech, Inc; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003); and receives research support from the NIH. Dr Graff-Radford is supported by the Mayo Clinic Myron and Jane Hanley Career Development Award in Stroke Research, and the National Institute On Aging of the National Institutes of Health under Award Number K76AG057015. Dr Arnold Fiebelkorn, Dr Rabinstein, and Mr Przybelski report no disclosures.
